Prostate Cancer Clinical Trials in Beijing, Beijing Municipality

35 recruitingBeijing, Beijing Municipality, China

Showing 120 of 35 trials

Recruiting
Phase 3

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled281 locationsNCT06925737
Recruiting
Phase 3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled324 locationsNCT06136650
Recruiting
Phase 2

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer320 enrolled44 locationsNCT04606446
Recruiting
Phase 3

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Prostate Cancer Metastatic
Merck Sharp & Dohme LLC1,310 enrolled282 locationsNCT06136624
Recruiting
Not Applicable

Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis

Prostate Cancer (Diagnosis)
Peking University First Hospital592 enrolled1 locationNCT07460843
Recruiting
Phase 1

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

Prostate Cancer
Astellas Pharma Global Development, Inc.12 enrolled1 locationNCT07339267
Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer
Celgene960 enrolled279 locationsNCT06764485
Recruiting
Not Applicable

Adaptive Radiotherapy for Genitourinary Cancers

Bladder CancerProstate Cancer (Post Prostatectomy)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences60 enrolled1 locationNCT07324798
Recruiting
Phase 1Phase 2

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

Metastatic Castration-resistant Prostate Cancer
Hinova Pharmaceuticals Inc.84 enrolled27 locationsNCT06155084
Recruiting
Not Applicable

MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)

Radiotherapy Side EffectProstate CancerOligometastatic Disease+4 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences50 enrolled1 locationNCT05183074
Recruiting

MR Microstructural Imaging for Prostate Cancer Diagnosis

Prostate CancerDiffusion MRI
First Affiliated Hospital of Zhejiang University2,000 enrolled6 locationsNCT07249281
Recruiting
Not Applicable

68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients

Prostate Cancer
Peking Union Medical College Hospital50 enrolled1 locationNCT05324332
Recruiting
Not Applicable

Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer

Prostate CancerOligometastatic Prostate Cancer
Peking University First Hospital390 enrolled3 locationsNCT07015138
Recruiting
Not Applicable

Diagnostic Efficacy and Safety of Flotufolastat F-18 Injection in Subjects With Biochemical Recurrence of Prostate Cancer

Prostate Cancer
Sinotau Pharmaceutical Group121 enrolled1 locationNCT07115277
Recruiting
Not Applicable

Evaluation of Targeted Biopsy Plus Sextant Biopsy in Diagnosis of Prostate Cancer

Prostate Cancer
Peking University First Hospital300 enrolled1 locationNCT06684652
Recruiting
Not Applicable

Optimizing Prostate Biopsy Schemes in Men With Multiple mpMRI Visible Lesions

Prostate Cancer
Peking University First Hospital400 enrolled1 locationNCT06841211
Recruiting
Not Applicable

The Role of Levator Ani Muscle Reconstruction Technology in Urinary Incontinence Recovery

Prostate Cancer
Peking University First Hospital192 enrolled1 locationNCT06543420
Recruiting
Phase 2

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

Castration-resistant Prostate Cancer
RemeGen Co., Ltd.40 enrolled3 locationsNCT06227156
Recruiting
Phase 1Phase 2

Study of [177Lu] Lu-XT033 Injection in Patients With Metastatic Prostate Cancer

Prostate Cancer
Sinotau Pharmaceutical Group32 enrolled2 locationsNCT06081686
Recruiting

Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis

Breast CancerLiver CancerColorectal, Cancer+10 more
Beijing Friendship Hospital2,700 enrolled4 locationsNCT06363123